

NDLR 2018 POSTER LISTING

Updated 12/03/2018

Poster Number	Presenter Name	Paper Title	Affiliation
1	Sadia Afrin	Targeted Next-Gen Sequencing for Detecting MLL Gene Fusions in Leukemia.	University of Queensland
2	Melissa Bennett	Inhibition of glucosylceramide synthase causes multiple myeloma cell death alone and in synergy with bortezomib via enhanced endoplasmic reticulum stress	Centre for Cancer Biology
3	Kavita Bisht	Prolylhydroxylase inhibitor FG-4497 enhances haematopoietic stem cell mobilisation via vascular endothelial growth factor receptor 2	Mater Research Institute
4	Stefan Bjelosevic	Delineating functional dependencies of NRASG12D and FLT3-ITD driver mutations in MLL-rearranged acute myeloid leukaemia	Peter MacCallum Cancer Centre
5	Margs Brennan	The E3 Ubiquitin Ligase HectD1 is Critical for Haematopoietic Stem Cell Function	Walter and Eliza Hall Institute of Medical Research
6	Lauren Brown	Exploring signalling by ABL1 fusions using SILAC based phosphoproteomics	Murdoch Children's Research Institute
7	Claudia Bruedigam	Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in Acute Myeloid Leukemia (AML)	QIMR Berghofer Medical Research Institute
8	Gabriela Brumatti	Exploiting the alternative cell death pathway necroptosis to treat Acute Myeloid Leukaemia	Walter and Eliza Hall Institute of Medical Research
9	Catherine Carmichael	The EMT Modulator SNAI1 Drives AML Development Via Its Interaction with the Histone Demethylase LSD1	Monash University
10	Jesse Cheah	Germline SAMD9L mutations predispose to cytopenias and haematological malignancy	Centre for Cancer Biology
11	Yu-Chen Enya Chen	Activation of FcγR-dependent responses to therapeutic antibodies by Nurse Like cells requires PI3Kδ	University of Queensland Diamantina Institute
12	Laurence Cheung	Dissecting the pre-B leukaemia bone marrow microenvironment	Telethon Kids Institute
13	Joanne Davis	Targeting NK cells via BCL2 inhibition improves stem cell transplant outcomes	The Royal Melbourne Hospital
14	Rhea Desai	Clonal Evolution in Murine Leukaemia Models	The University of Auckland
15	Matt Dun	Intracellular oxidative stress contributes to the oncogenic potential of mutant FLT3 in acute myeloid leukaemia patients, and is a synergistic treatment target	Hunter Medical Research Institute
16	Laura Eadie	Mutations to the transcription factor MYB alter cellular localization and decrease degradation likely enhancing oncogenicity in patients with T-cell ALL	SAHMRI
17	Sarah Ellis	PAR3 acts through the Hippo pathway to suppress development of Acute Myeloid Leukemia.	Peter MacCallum Cancer Centre
18	Johanna Erbani	Vascular niche E-selectin plays a key role in leukaemia chemo-resistance	Mater Research Institute
19	Kathryn Evans	Efficacy of the AKR1C3-activated prodrug OBI-3424 against preclinical models of T-cell acute lymphoblastic leukaemia	Children's Cancer Institute
20	Laura Ferguson	Targeting ribosome biogenesis and autophagy as a novel combination therapy strategy to treat acute myeloid leukemia	The John Curtin School of Medical Research
21	Natasha Friend	SAMSN1 inhibits the metastasis of multiple myeloma cells	The University of Adelaide
22	Steven Goossens	Targeted immunotherapy for T-ALL using AcTafersons	Ghent University
23	Christopher Hahn	Duplication on chromosome 14q associates with familial predisposition to a novel myelodysplastic syndrome (MDS)/Myeloproliferative Neoplasms (MPN) overlap phenotype	SA Pathology
24	Minhee Halemba	Exploring acute myeloid leukaemia (AML) bioenergetics and drug sensitivity by rendering AML cell lines impaired for either Glycolysis or Oxidative phosphorylation	Monash University
25	Michelle Henderson	Inhibition of NAD biosynthesis as a novel therapy for MLL-rearranged acute lymphoblastic leukaemia	Children's Cancer Institute
26	Michelle Henderson	A novel compound that selectively kills a subset of MLL-rearranged leukaemia cells by inducing mitochondrial dysfunction	Children's Cancer Institute
27	Keisuke Horikawa	Oncogenic MYD88 L265P mutation in B cell malignancies	JCSMR, ANU
28	Jacob Jackson	Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukaemia in mice	The Australian Centre for Blood Diseases
29	Sabine Jurado	Rapid formation of B cell leukemia in mice expressing the PAX5-JAK2 fusion protein	IMP
30	Thomas Keech	Macrophage Involvement in the Response of Acute Myeloid Leukaemia to Chemotherapy	Mater Research Institute
31	Rachel Koldej	Genetic Biomarkers pre- and post-treatment predict clinical response and survival in Myelodysplasia	Royal Melbourne Hospital
32	Hansen Kosasih	Novel KMT2A Fusions in Paediatric Leukaemia	Murdoch Children's Research Institute
33	Erin Lawrence	Investigating the role of mutant DNMT3a in Acute Myeloid Leukaemia and other cancers	Walter and Eliza Hall Institute of Medical Research
34	Victoria Ling	Implementation of a genome-wide CRISPR screen to identify genetic determinants of resistance to combination chemotherapy in acute myeloid leukaemia	QIMR Berghofer Medical Research Institute
35	Jessica Lisle	EphA3 is critical for normal haematopoietic stem cell function	University of Queensland Diamantina Institute
36	Liu Lu	TGF-α predicts TKI treated CML patients who fail to achieve early molecular response	SAHMRI
37	Kyle MacBeth	Mechanisms of response to enasidenib therapy in relapsed or refractory acute myeloid leukemia (R/R AML) patients	Celgene Corporation
38	Kylee MacLachlan	Novel Combination Therapies with the RNA Polymerase I Inhibitor CX-5461 Significantly Improve Efficacy in Multiple Myeloma	VCCC/University of Melbourne
39	Hannah McCalmont	Combined BET and CDK9 inhibition results in synergistic in vivo efficacy against preclinical models of MLL-rearranged acute leukaemia	Children's Cancer Institute

NDLR 2018 POSTER LISTING
Updated 12/03/2018

40	Barbara McClure	Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion	SAHMRI
41	Emma Morrish	Pumping up Smac-mimetic therapy: a novel combined therapy to overcome treatment resistance in Acute Myeloid Leukaemia	Walter and Eliza Hall Institute of Medical Research
42	Donia Moujalled	A Dual BH3-mimetic approach targeting BCL-2 and MCL1 is highly efficacious and well-tolerated in Acute Myeloid Leukemia	Monash University
43	Heather Murray	Targeting DNA repair in FLT3-mutant Acute Myeloid Leukaemia	University of Newcastle
44	Nisha Narayan	MicroRNA-211 – A Novel Oncogene in Acute Myeloid Leukemia	Murdoch Children's Research Institute
45	Steven Ngo	Concurrent granulocyte and monocyte/macrophage AML maturation in a mouse model of differentiation therapy.	Australian Centre for Blood Diseases
46	Ethan Oxley	Molecular mechanisms whereby PU.1 activity reversibly controls AML differentiation state	ACBD
47	Ilaria Stefania Pagani	Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients.	SAHMRI
48	Andrew Perkins	Direct targets of pSTAT5 signaling in erythropoiesis and myeloproliferative neoplasms	Monash University
49	Jason Powell	Targeting sphingosine kinase 1 induces Mcl-1 dependent cell death in acute myeloid leukaemia	Centre for Cancer Biology
50	Benjamin Schreiber	Validating Predictive Genetic and Clinical Risk Factors for Treatment-Related Toxicities in Children with Acute Lymphoblastic Leukemia.	Children's Cancer Institute
51	Chia Sharpe	Gene expression profiling using NanoString allows profiling of peripheral blood immune subsets comparable to flow cytometry in leukaemia patients	Melbourne Health
52	Ben Shields	The oncoprotein NUP98-HOXD13 (NHD13) induces thymocyte self-renewal via Lmo2/Ly11, however this is not required for NHD13-induced T-ALL	Australian Centre for Blood Diseases
53	Jake Shortt	DNMT1 depletion by SGI110 (Guaecitabine) induces potent anti-T-cell lymphoma activity in vitro and in vivo	Monash University
54	Chris Slape	Long-term self renewal of pre-leukemic T-ALL stem cells requires EphA3	University of Queensland Diamantina Institute
55	Jasmin Straube	The impact of age, NPM1mut and FLT3ITD allelic ratio in patients with acute myeloid leukemia	QIMR Berghofer Medical Research Institute
56	Shuhying Tan	Altered expression of Hoxa1 perturbs normal haematopoiesis, depletes haematopoietic stem cells, and is sufficient to induce myelodysplasia in mice	St. Vincent's Institute
57	Joshua Tay	Prostaglandin I2 as a novel haematopoietic stem cell niche factor	Mater Research Institute
58	Lauren Thurgood	Hooked on fat: metabolic dysfunction in chronic lymphocytic leukaemia	Flinders University
59	Cedric Tremblay	Inhibition of Receptor-Mediated Endocytosis Impairs Leukemia-Propagating Cells Function	Monash University
60	Pieter Van Vlierberghe	A novel mouse model to study the oncogenic role of MYB in T-cell acute lymphoblastic leukemia	Ghent University
61	Pieter Van Vlierberghe	Decitabine as a new therapeutic agent for T-cell acute lymphoblastic leukemia	Ghent University
62	Parvathy Venugopal	Revertant Somatic Mosaicism in Haematological Disorders	Centre for Cancer Biology
63	Anh Vo	Functional Analysis of Critical Regions of the Haematopoietically-Expressed Homeobox Gene (Hhex) Required for Growth of Acute Myeloid Leukaemia	ABCD
64	Therese Vu	Overexpression of the transcription factor Cdx2 in haematopoietic stem cells predisposes to haematological malignancies	QIMR Berghofer Medical Research Institute
65	Jackie Wang	Zeb1 and Zeb2 act as key determinants in myeloid differentiation: a potential therapeutic target in acute myeloid leukaemia?	Monash University
66	Matthew Witkowski	Dissecting the prognostic impact of the acute leukaemia immune microenvironment using single-cell approaches	NYU School of Medicine
67	Alex Wong	NxtIRF: A novel computational approach to measure differential intron retention in cancer databases	Centenary Institute
68	Angela (Jinhan) Xie	Development of a predictive clofarabine-based preclinical treatment regimen for the personalised treatment of acute lymphoblastic leukaemia	Children's Cancer Institute
69	Jane Jialu Xu	Srsf2 P95H mutation promotes myeloid biased haematopoiesis and initiates myeloproliferative/myelodysplastic syndrome from hematopoietic stem cells	St Vincent's Institute